Welcome to our dedicated page for XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock news (Ticker: XOMAO), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock stock.
XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock (symbol: XOMAO) is a biotechnology royalty aggregator specializing in acquiring future economics associated with pre-commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies. The company has an extensive portfolio of assets, including licenses for therapeutic candidates designed to improve human health. XOMA's recent achievements include earning milestone payments related to FDA approvals, acquiring economic interests in various assets, and initiating share buyback programs.
Rhea-AI Summary
XOMA Corporation (NASDAQ: XOMA) announced that the FDA has accepted Zevra Therapeutics' New Drug Application for arimoclomol, a first-in-class therapy for Niemann-Pick disease type C (NPC), with a PDUFA target action date of June 21, 2024. XOMA will make a $1 million milestone payment to LadRx based on the FDA's acceptance. The company previously paid LadRx a $5 million upfront payment and acquired a mid-single digit royalty on arimoclomol's commercial sales, with potential milestone payments of up to $52.6 million, net, from Zevra. The transaction also included a royalty rate on commercial sales of aldoxorubicin and potential payments of up to $343 million in development and commercial milestones from ImmunityBio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
-
Rhea-AI Summary
XOMA Corporation (XOMA) announced the appointment of Owen Hughes as Chief Executive Officer and Jack L. Wyszomierski as Chairman of the Board. Hughes has been serving as XOMA's Executive Chairman and Interim CEO since January 1, 2023. The Board aims to establish XOMA as a premier biotech royalty aggregator, focusing on accelerating growth and maximizing value for stockholders. The company's growing cash receipts and maturing portfolio reflect significant inflection points within its established royalty and milestone acquisition strategy. XOMA also boasts the largest cash balance in its history.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
-
Rhea-AI Summary
XOMA Corporation (Nasdaq: XOMA) announces its first stock repurchase program, authorizing the purchase of up to $50 million of common stock through January 2027. The company aims to maximize shareholder value through prudent capital allocation, leveraging future cashflow streams of its growing royalty portfolio to generate superior risk-adjusted, non-correlated returns for investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
Rhea-AI Summary
XOMA Corporation (Nasdaq: XOMA) announced cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) will receive a cash dividend of $0.53906 per share, while holders of depositary shares for XOMA’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO) will receive a cash dividend of $0.52344 per depositary share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
-
Rhea-AI Summary
XOMA Corporation (Nasdaq: XOMA) secures $140 million non-dilutive, non-recourse, royalty-backed loan from Blue Owl Capital Inc. (NYSE: OWL) to fund stock repurchases and additional royalty and milestone acquisitions. The loan is repayable over a 15-year period at a fixed interest rate of 9.875% per year, with the option to draw an additional $10 million based on VABYSMO® (faricimab) sales. XOMA has also issued warrants to purchase up to 120,000 shares of its common stock to Blue Owl at implied premiums of 122%, 170%, and 217% to the closing stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.6%
Tags
-
Rhea-AI Summary
XOMA Corporation reported $6.6 million in cash receipts, a NDA filing, and anticipated Phase 3 program initiation, with third-quarter 2023 revenues of $0.8 million and G&A expenses of $6.4 million. The company received a $4.9 million cash payment from Roche and earned a $5 million milestone related to the FDA's acceptance of Day One Biopharmaceuticals' NDA for tovorafenib.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
Rhea-AI Summary
XOMA Corporation announces earning a $5 million milestone for the FDA acceptance of Day One Biopharmaceuticals' New Drug Application (NDA) for tovorafenib as a monotherapy for relapsed or progressive pediatric low-grade glioma (pLGG). The FDA has granted Priority Review and set a PDUFA date of April 30, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
-
Rhea-AI Summary
XOMA Corporation announces cash dividends for Series A and Series B Cumulative Preferred Stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
-
Rhea-AI Summary
XOMA Corporation to present company update at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
FAQ
What is the current stock price of XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock (XOMAO)?
The current stock price of XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock (XOMAO) is $25.56 as of December 23, 2024.
What does XOMA Corporation specialize in?
XOMA is a biotechnology royalty aggregator that acquires future economics associated with pre-commercial therapeutic candidates.
What recent achievements has XOMA had?
XOMA has earned milestone payments from FDA approvals, acquired economic interests in assets, and initiated share buyback programs.
What is XOMA's extensive portfolio comprised of?
XOMA's portfolio includes licenses for therapeutic candidates aimed at improving human health.
What is unique about XOMA's approach to capital deployment?
XOMA focuses on accelerating value creation with a disciplined approach to capital deployment.
What significant event has XOMA recently experienced related to FDA approvals?
XOMA has recouped its initial capital outlay and anticipates future royalties from OJEMDA™, a therapy for relapsed or refractory pLGG driven by BRAF fusions.
How does XOMA support biotech companies?
XOMA provides non-dilutive, non-recourse funding to biotech companies by acquiring future economics associated with their licensed therapeutic candidates.
What financial results did XOMA report for the first quarter of 2024?
XOMA recorded total revenues of $1.5 million, increased R&D expenses, and achieved a net loss of $8.6 million for the quarter.
What recent acquisitions has XOMA made?
XOMA acquired an economic interest in three women's health assets from Daré Bioscience, Inc., for an upfront payment of $22 million.
How does XOMA plan to drive sustainable free cash flow generation?
XOMA anticipates that future royalties, including those from OJEMDA™, will contribute to a growing portfolio of royalty receipts supporting sustainable free cash flow generation.
What sets XOMA apart in the biotechnology industry?
XOMA's focus on acquiring future economics from licensed therapeutic candidates and providing funding to biotech companies sets it apart in the industry.
XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock